Phase II Study of Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
For locally advanced gastric/gastroesophageal junction adenocarcinoma (cT3/4aN+M0 ),
neoadjuvant therapy can downstage T and N stage, improve R0 resection rate, reduce recurrence
and metastasis rates, and finally improve the long-term survival. A combination of
Fruquintinib and SOX for locally advanced gastric/gastroesophageal junction adenocarcinoma
could be a novel therapy. This study intends to evaluate the efficacy of Fruquintinib plus
SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction
adenocarcinoma.